Novel regimens for treatment of <i>Mycobacterium avium</i> lung disease based on advanced <i>in vitro</i> systems and the mathematics of basis functions
=0.27, p=0.32), questioning ethambutol's role in the SOC. The BF framework is potentially easy to adapt for modeling other anti-infective agents across many infectious diseases.
Authors
- Shashikant Srivastava (ORCID: https://orcid.org/0000-0002-8786-8851)
- Tawanda Gumbo (ORCID: https://orcid.org/0000-0001-7592-8012)
- Gunavanthi D. Boorgula (ORCID: https://orcid.org/0000-0003-1749-3705)
- Pamela J. McShane (ORCID: https://orcid.org/0000-0003-1338-1407)
- Sanjay Singh (ORCID: https://orcid.org/0000-0003-4601-5673)
Institutions
- The University of Texas at Tyler (US)
- National Heart, Lung, and Blood Institute (US)
- Raptamer Discovery Group (United States) (US)
- Practical Action (ZW)
- Phasex (United States) (US)
- The University of Texas Health Science Center at Tyler (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-03-31
- DOI
- https://doi.org/10.64898/2026.03.30.715241
- Primary Topic
- Mycobacterium research and diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00